Sugi Predict

Sugi Predict / Compounds / SCHEMBL2319256

SCHEMBL2319256

SCHEMBL2319256

Fc1ccc(-c2cc(C(F)(F)F)on2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ STAT3 P40763 2/20 0.52
▸ MAPT P10636 2/20 0.52
▸ GALR3 O60755 1/20 0.52
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ KDM4E B2RXH2 5/20 0.45
▸ ALDH1A1 P00352 5/20 0.45
▸ RAB9A P51151 4/20 0.45
▸ PTGS2 P35354 2/20 0.45
▸ MITF O75030 1/20 0.45
▸ STAT1 P42224 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ TLR9 Q9NR96 1/20 0.45
▸ NPC1 O15118 3/20 0.43
▸ CXCR1 P25024 1/20 0.41
▸ ASIC1 P78348 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MAPK1 P28482 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15299348 0.85 MEN1 (0.47) LMNASMN1; SMN2STAT3MAPTGALR3
SCHEMBL28977122 0.84 RAB9A (0.51) LMNASMN1; SMN2STAT3MAPTGALR3
SCHEMBL2321001 0.84 RAB9A (0.51) LMNASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL26262561 0.84 MEN1 (0.69) LMNASMN1; SMN2STAT3MAPTGALR3
SCHEMBL28402085 0.84 MEN1 (0.64) LMNASMN1; SMN2STAT3MAPTGALR3
SCHEMBL24168675 0.84 MEN1 (0.46) LMNASMN1; SMN2STAT3MAPTGALR3
SCHEMBL7750952 0.83 MEN1 (0.68) LMNASMN1; SMN2STAT3MAPTGALR3
SCHEMBL11787918 0.81 S1PR1 (0.47) LMNASMN1; SMN2STAT3MAPTGALR3
SCHEMBL2320359 0.81 MEN1 (0.47) LMNASMN1; SMN2STAT3MAPTGALR3
SCHEMBL28405680 0.80 KIF11 (0.44) LMNASMN1; SMN2STAT3MAPTGALR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2767536-B1 Isoxazolo-pyridine derivatives HOFFMANN LA ROCHE (CH) 2015-09-02 — — EP disclosed
US-9073908-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2015-07-07 — — US disclosed
EP-2227467-B1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-12-31 — — EP disclosed
US-8877782-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 — — US disclosed
US-8877783-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-11-04 — — US disclosed
US-8846719-B2 Isoxazolo-pyridine derivatives ROCHE PALO ALTO LLC (US) 2014-09-30 — — US disclosed
EP-2767536-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2014-08-20 — — EP disclosed
US-20130281690-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-24 — — US disclosed
US-20130274468-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 — — US disclosed
US-20130274467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 — — US disclosed
US-20120184538-A1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-07-19 — — US disclosed
EP-2170873-B1 ISOXAZOLE-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 — — EP disclosed
CN-101965344-A Isoxazole-imidazole derivatives HOFFMANN LA ROCHE 2011-02-02 — — CN disclosed
US-7851469-B2 Isoxazole-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-14 — — US disclosed
EP-2227467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 — — EP disclosed
EP-2170873-A1 ISOXAZOLE-IMIDAZOLE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-04-07 — — EP disclosed
WO-2009071476-A1 ISOXAZOLO-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-11 — — WO disclosed
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES ROCHE PALO ALTO LLC 2009-06-04 — — US disclosed
US-20090005370-A1 ISOXAZOLE-IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-01-01 — — US disclosed
WO-2009000662-A1 ISOXAZOLE-IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143371-A1 ISOXAZOLE-PYRIDINE DERIVATIVES GABRA5, GABRA1, CHRNA5 LMNA 3918/4885SMN1; SMN2 3318/4885STAT3 3731/4885
US-20130274468-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 LMNA 3905/4885SMN1; SMN2 3354/4885STAT3 3722/4885
US-20090005370-A1 ISOXAZOLE-IMIDAZOLE DERIVATIVES GABRA5, GABRA1, GABRA4 LMNA 4329/4885SMN1; SMN2 3025/4885STAT3 3140/4885
US-20130274467-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 LMNA 3905/4885SMN1; SMN2 3354/4885STAT3 3722/4885
US-20130281690-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 LMNA 3905/4885SMN1; SMN2 3354/4885STAT3 3722/4885
US-20120184538-A1 ISOXAZOLO-PYRIDINE DERIVATIVES GABRA5, GABRA1, GABRA4 LMNA 3905/4885SMN1; SMN2 3354/4885STAT3 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.